Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Key committee was asked to fast-track a decision on the antibody cocktail, but lack of mortality data could mean patchy uptake seen in US repeated in the EU.

The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.

Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.

While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.

As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.